This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

DNA Microarray 2013: A Focus On Sales Growth

NEW YORK, Feb. 6, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

DNA Microarray 2013: A Focus on Sales Growth

http://www.reportlinker.com/p0980749/DNA-Microarray-2013-A-Focus-on-Sales-Growth.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genetically_Modified_Organism,_GMO

DNA Microarray 2013 presents the findings of a global market study of DNA Microarray, involving the participation of 201 buyers and end-users in this field. With a focus on market development, sales growth and commercial opportunities, the study profiled current and evolving areas of this market, as outlined below. Its findings provide valuable product and market information, and decision-making support to suppliers in the DNA Microarray field.

From the early use of miniaturised microarrays for the analysis of gene expression in the mid 1990s, this technique has established markets that are expected to reach $3 billion by 2015. However, these are also changing as new applications are developed and new competitive strategies, such as PCR, grow. This report, based on an analysis of current and evolving developments in the DNA microarray field, has been produced to assist marketing and sales in this field, and the identification of new opportunities. It is the outcome of an extensive global study involving more than 200 experienced DNA microarray buyers and end-users. It's findings provide a "focus on sales growth" to developers and vendors in the microarray field, and the changes that are driving these developments. The following indicate the key market areas covered in the study:
  • Routine use: Use of DNA microarrays by end-users for running routine (developed and validated) microarray tests, the development or validation of microarray tests and for the qualitative discovery using microarray methods
  • Suppliers: Purchases of DNA microarrays and related systems by end-users from more than 30 companies and anticipated DNA microarray purchases by end-users from more than 30 companies over the next three years, each ranked according to their competitive position.
  • Methods: Current use of more than 15 DNA microarray methods by end-users and the anticipated use of these methods by end-users over the next three years, each ranked according to their competitive position.
  • Applications: Current use of more than 20 DNA microarray applications by end-users and the anticipated use of these applications by end-users over the next three years, each ranked according to their competitive position.
  • Preferred Companies: End-users' preferred companies in the DNA microarray field, each ranked according to their competitive position.
  • Products: End-users' preferred products (and associated companies) in the DNA microarray field, each ranked according to their competitive position.
  • Strengths: End-users' disclosures of the strengths of their preferred products in the DNA microarray field, each ranked according to their competitive position.
  • Weaknesses: End-users' disclosures of the weaknesses of their preferred products in the DNA microarray field, each ranked according to their relative position.
  • Financial Budgets: End-users' annual financial budgets for DNA microarray studies.
  • Budget Breakdown: The breakdown of end-users' DNA microarray financial budgets in eight key areas, relating to their current expenditure on DNA microarray products and activities.
  • Future Budget Breakdown: The breakdown of end-users' microarray financial budgets in eight key areas, relating to their anticipated expenditure over the next three years, on DNA microarray products and activities.
  • Future Budgets: End-users' anticipated changes (percentage increases or decrease) over the next three years, relating to their DNA microarray activities
  • Consumables: End-users' top three consumables, associated with their DNA microarray activities.
  • Quality Control: End-users' adherence to established quality control guidelines or procedures (e.g. MAIME), relating to the conduct of DNA microarray studies.
  • Challenges: End-users' disclosures on molecular types that present the greatest technical challenges to DNA microarray analysis, together with the associated sample types (matrices), associated microarray methods and underlying reasons.
  • Innovation: End-users' current needs relating to 12 key areas of required innovation in the DNA microarray field, each ranked (on a scale of 1 to 10) according to their importance.
  • Recent Innovations: End-users disclosures on the most important innovations relating to their use of DNA microarrays, over the last three years.
  • Future Innovation: End-users' disclosures on what they anticipate will be the most important innovations in the DNA microarray field, over the next three years.
  • Biomarkers: End-users' application of DNA microarray methods for the study of disease biomarkers, including molecular types and their clinical utilities.
  • Organisations: End-users organisations include clinics or hospitals, government bodies, large international companies, research institutes, small and medium sized companies, universities and veterinary centres.
  • Fields: End-users underlying fields include biotechnology, chemicals, clinical or hospital, defence, energy, environmental, food and drink, forensics, geology, government, healthcare, natural products, pharmaceuticals, research institutes, security and universities.
  • Bioinformatics Software: End-users' disclosures on their preferred bioinformatics software, associated with DNA microarray studies.
  • Purpose: End-users' underlying reasons for using DNA microarray analysis across 13 major fields (biotechnology, chemicals, clinical or hospital, defence, energy, environmental, food and drink, forensics, geology, government, healthcare, natural products, pharmaceuticals, research institutes, security, university), each ranked according to their relative importance.
  • Samples: Study sample types analysed by end-users using DNA microarray methods, each ranked according to their relative importance.
  • Sample Preparation: The use of sample preparation methods by end-users for DNA microarray studies, each ranked according to their importance. 

Executive Summary

Chapter 1 Introduction

Chapter 2 Study Participants

2.1 This Chapter

1 of 8

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,776.91 +93.33 0.53%
S&P 500 2,081.34 +12.58 0.61%
NASDAQ 4,997.4590 +5.5190 0.11%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs